Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

I-Mab Completes $104 Million NASDAQ IPO to Develop Biologics Portfolio

publication date: Jan 17, 2020

I-Mab, a Shanghai biotech, raised $104 million in its IPO on the NASDAQ exchange to support its portfolio of more than ten biologic products. I-Mab was founded in 2016 by C-Bridge Capital and Tasly Pharma, which merged two China companies, Third Venture Biotech and Tasgen Bio, and invested $150 million in newly formed I-Mab. The offering was priced at $14 per ADS, the middle of the expected range, but the price has moved 10% lower to $12.58 in initial trading. More details....

Stock Symbol: (NSDQ: IMAB)

Share this with colleagues:

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022